Blog

Jason Mouabbi: Excitement is Building for ASCO25

Jason A. Mouabbi/X

May 26, 2025, 06:10

Jason Mouabbi: Excitement is Building for ASCO25

Jason Mouabbi, Assistant professor of breast medical oncology at The University of Texas MD Anderson Cancer Center, shared a post on LinkedIn:

“Excitement is building for ASCO25, where 3 pivotal studies are set to redefine treatment across all three subtypes of metastatic breast cancer. A major moment for the breast cancer community.

1. SERENA6_Trial: Camizestrant (SERD) + CDK4/6 Inhibitor for HR+/HER2− Advanced Breast Cancer with Emergent ESR1 Mutations

Abstract: LBA4
Presentation: Plenary Session
Date and Time: Sunday, June 1, 2025, 2:41 PM – 2:53 PM CDT

Why is it important: Since the inception of our profession we’ve treated mBC until clinical/radiological progression. Does switching the ET backbone when detecting an emergent ESR1 mutations (molecular progression) before any evidence of radiological/clinical progression improve outcomes in HR+/HER2− breast cancer?

This will lead to a paradigm shift in the way we monitor and treat our patients and will certainly lead to a boom in ctDNA testing!

2. DESTINYBreast09_Trial: Trastuzumab Deruxtecan (T-DXd) ± Pertuzumab vs. THP for 1L HER2+ mBC

Abstract: LBA1008
Presentation: Oral Abstract Session
Date and Time: Monday, June 2, 2025, 7:30 AM – 7:42 AM CDT

Why is it important: For over a decade, the CLEOPATRA regimen (THP) has been the cornerstone treatment for patients with 1L HER2+ mBC. This is the era of ADCs! Will T-DXd ± Pertuzumab dethrone THP and be the next SoC?

3. ASCENT04/KEYNOTED19 Trial: Sacituzumab Govitecan (SG) + Pembrolizumab vs. Chemotherapy + Pembrolizumab in PD-L1+ (CPS ≥10) TNBC

Abstract: LBA109
Presentation: Oral Abstract Session
Date and Time: Saturday, May 31, 2025, 3:35 PM – 3:47 PM CDT

Why is it important: As stated above this is the era of ADCs! Will SG be the next SoC in 1L TNBC?

ASCENT04 is looking at SG + pembrolizumab (immunotherapy) is the cohort of TNBC that are PD-L1+ (CPS ≥10) which account of ~40% of patients. ASCENT03 is looking at SG in the cohort that is PD-L1 negative (~60%) and based on a recent press release that too will be a game changer!”

More posts featuring Jason A. Mouabbi.